Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:combination_drug
|
| gptkbp:approvedBy |
gptkb:FDA
2000 |
| gptkbp:ATCCode |
P01BB51
|
| gptkbp:brand |
Malarone
|
| gptkbp:contraindication |
severe renal impairment
|
| gptkbp:developedBy |
GlaxoSmithKline
|
| gptkbp:hasComponent |
gptkb:proguanil
gptkb:atovaquone |
| gptkbp:indication |
gptkb:Plasmodium_falciparum_malaria
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits mitochondrial electron transport (atovaquone)
inhibits dihydrofolate reductase (proguanil) |
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting abdominal pain headache |
| gptkbp:usedFor |
malaria treatment
malaria prevention |
| gptkbp:WHOModelListOfEssentialMedicines |
yes
|
| gptkbp:bfsParent |
gptkb:Plasmodium_falciparum
gptkb:Plasmodium_falciparum_malaria |
| gptkbp:bfsLayer |
7
|
| http://www.w3.org/2000/01/rdf-schema#label |
atovaquone-proguanil
|